Estimaciones de analistas de Wall Street para Curis, Inc. (CRIS): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 16 |
| Mantener | 2 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 18 |
| Calificación media (1-5) | 0.89 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-2.29 | ||
| 2026-08-14 | $-4.02 | $-6.95 | +42.2% |
| 2026-05-12 | $-25.00 | $-5.80 | -331.0% |
| 2026-03-19 | $24.60 | $-8.72 | +382.1% |
| 2025-11-06 | $-9.80 | $-12.40 | +21.0% |
| 2025-08-05 | $-13.60 | $-39.80 | +65.8% |
| 2025-05-06 | $-25.00 | $-22.80 | -9.6% |
| 2025-03-31 | $-25.00 | $-27.20 | +8.1% |
Ratios de valoración
| Precio / Valor contable | 0.48 |
| EV / EBITDA | 0.09 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $7.5M | $9.9M | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Coste de Ventas | $399000 | $496000 | $563000 | $503000 | $534000 | $533000 | $257000 | $212000 | $98000 | $45000 |
| Beneficio Bruto | $7.1M | $9.4M | $9.9M | $9.5M | $10.3M | $10.1M | $9.9M | $9.8M | $10.8M | $9.4M |
| I+D | $31.6M | $33.3M | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M |
| Generales y Administrativos | $15.6M | $25.8M | $14.8M | $11.6M | $12.1M | $17.3M | $19.6M | $18.6M | $16.8M | $14.0M |
| Gastos Operativos | $47.2M | $59.2M | $39.2M | $33.9M | $35.2M | $52.2M | $62.9M | $58.1M | $55.4M | $42.3M |
| Beneficio Operativo | -$58.0M | -$49.8M | -$29.3M | -$24.4M | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$32.9M |
| EBITDA | -$57.4M | -$49.1M | -$28.5M | -$27.2M | -$24.7M | -$40.8M | -$51.7M | -$45.1M | -$42.6M | -$5.2M |
| Gastos por Intereses | $2.8M | $4.0M | $3.9M | $4.8M | $5.1M | $4.5M | $4.8M | $2.0M | $615000 | $2.2M |
| Beneficio Antes de Impuestos | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| BPA | $-900.00 | $-3575.20 | $-393.40 | $-387.40 | $-245.80 | $-198.40 | $-242.80 | $-179.20 | $-137.60 | $-11.60 |
| BPA Diluido | $-900.00 | $-3575.20 | $-393.40 | $-387.40 | $-245.80 | $-198.40 | $-242.80 | $-179.20 | $-137.60 | $-11.60 |
| Acciones en Circulación (Diluidas) | $66392 | $14913 | $82795 | $82951 | $121675 | $228922 | $233481 | $264664 | $315314 | $658201 |
Precio
| Precio | $1.12 |
| Capitalización | $2M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explorar sector: Healthcare · Biotechnology
Más secciones de CRIS: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones